RxDoctor Payments Data

Jennifer Allen, MD

Internal Medicine · Danville, INNPI 1386937258

Payments from drug & device makers

$859in general payments, 2019–2025

Across 45 payments — averaging $19.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$252
  • Pfizer$132
  • GSK$102
  • AstraZeneca$71
  • Lilly USA, LLC$66
  • Abbott$54
  • plus $183 from 11 others

What the payments were for

  • Food & beverage$84799%
  • Education$121%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$859 in reported general payments places this provider in the 70th percentile of 1,747 internal medicine providers in Indiana.

See all internal medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$83,637
Medicare patients
193
Services billed
983

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide84$107,964
JardianceEmpagliflozin44$56,639
OzempicSemaglutide54$50,912
EliquisApixaban33$46,737
RybelsusSemaglutide12$25,288
XareltoRivaroxaban12$17,579
Breo ElliptaFluticasone/Vilanterol25$17,536
Trelegy ElliptaFluticasone/Umeclidin/Vilanter24$15,310
TrulicityDulaglutide12$15,104
MyrbetriqMirabegron11$10,698
LyricaPregabalin12$10,632
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr13$7,248
Spiriva HandihalerTiotropium Bromide13$6,420
Stiolto RespimatTiotropium Br/Olodaterol Hcl12$5,703
Gabapentin167$4,492

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$66$123,06896 claims
Novo NordiskOzempic, Rybelsus$252$76,19966 claims
Boehringer IngelheimJardiance, Stiolto Respimat$17$62,34256 claims
PfizerEliquis, Lyrica$132$57,36945 claims
GSKBreo Ellipta, Trelegy Ellipta, Anoro Ellipta$102$40,09362 claims
Astellas Pharma US IncMyrbetriq$17$10,69811 claims
AstraZenecaSymbicort$71$2,56013 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,747 internal medicine providers in Indiana.

Other internal medicine in Danville

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →